MOH (Iraq)

Iraq MoH (Ministry of Health — Republic of Iraq) — operating through the Iraqi Technical Affairs Directorate + the Kimadia State Company for Marketing Drugs and Medical Appliances + the National Center for Drug Control and Research (NCDCR) + the Iraqi Pharmacovigilance Center — is the federal national regulatory authority for human medicines + biologicals + vaccines + medical devices + IVDs + cosmetics + dietary supplements + pharmacy practice + controlled substances across the Republic of Iraq. Iraq MoH operates under Law 40 of 1970 (Pharmacy Practice + Pharmaceutical Establishments) + Drug Registration framework + Law 68 of 1965 (Narcotics + Psychotropics) + subsequent Ministerial Orders + Technical Affairs Directorate Decisions + Guidance Documents.

Iraq MoH organisational structure includes:

• Minister of Health — political head appointed by the Council of Ministers.
• Deputy Minister + Director General of the Ministry of Health.
• Technical Affairs Directorate — the principal medicines + medical-device regulator coordinating Drug Registration + Pharmaceutical Inspection + Pharmacovigilance + Medical Devices + Pharmacy Practice.
• Drug Registration Department — drug + biological + vaccine + biosimilar + generic-medicine registration.
• Pharmaceutical Inspection Department — GMP + GDP + GPP + GVP + GLP inspections of Iraqi + foreign manufacturing facilities.
• Medical Devices Department — medical-device + IVD registration + matériovigilance.
• Pharmacy Practice Department — pharmacy + pharmaceutical-establishment licensing.
• Cosmetics + Dietary Supplements Department — cosmetic-product + dietary-supplement notification.
• Controlled Substances Department — narcotics + psychotropics framework coordination with INCB + Ministry of Interior + Iraqi Customs.
• Kimadia — State Company for Marketing Drugs and Medical Appliances — distinctive State-owned pharmaceutical + medical-device procurement + distribution company handling the dominant share of Iraqi public-sector procurement + distribution; substantively unique within the Arab region in scale + scope.
• National Center for Drug Control and Research (NCDCR) — central pharmaceutical QC laboratory + applied pharmaceutical research centre; pursuing ISO/IEC 17025 expansion + WHO PQ-Lab designation.
• Iraqi Pharmacovigilance Center — WHO PIDM-affiliated national PV centre.
• Iraqi National Cancer Research Center + Iraqi Center for Cardiac Diseases + Iraqi National Diabetes Center — disease-area research centres supporting clinical research + post-market surveillance.
• International Affairs Section — WHO + EMA + FDA + Arab League + EMRO coordination.

Iraq's distinctive federal-regional regulatory structure: the Republic of Iraq operates under a federal constitution (2005) with the Kurdistan Region of Iraq (KRI — three Governorates: Erbil + Sulaymaniyah + Duhok) operating a constitutionally-distinct Kurdistan Regional Government (KRG) Ministry of Health pharmaceutical framework headquartered in Erbil. The KRG MoH operates parallel Drug Registration + Pharmaceutical Inspection + Pharmacovigilance + Kurdistan Region pharmaceutical procurement via the KRG Kimadia-equivalent (Kurdistan Region General Directorate of Pharmaceuticals + Medical Appliances Procurement). Foreign manufacturers + sponsors targeting all of Iraq must engage both federal Iraq MoH (Baghdad — covering ~38 million population across 15 Governorates) + KRG MoH (Erbil — covering ~6 million population across 3 Governorates) with substantively parallel but distinct registration procedures + procurement frameworks. This federal-regional duality is the most operationally significant feature of Iraqi pharmaceutical market access + is frequently overlooked by foreign manufacturers.

Iraq MoH is distinct from + complementary to: Kimadia (State-owned pharmaceutical procurement + distribution); the Iraqi Syndicate of Pharmacists (professional licensing body for individual pharmacists); the Iraqi pharmaceutical-manufacturing industry historically organised under State Company for Drug Industries (SCDI) / Samarra Drug Industries (SDI) / Nineveh Drug Industries (NDI) State-owned manufacturers + emerging private-sector manufacturers; Iraqi medical schools + pharmacy faculties (University of Baghdad + Al-Mustansiriya University + University of Mosul + University of Basra + University of Kufa + KRI medical schools — University of Salahaddin + University of Sulaimani + University of Duhok); and UN-agency + NGO healthcare operators including WHO + UNICEF + UNHCR + UNFPA + UNDP + ICRC + IRC + MSF supporting substantial humanitarian + reconstruction healthcare programmes. Iraq's pharmaceutical environment is uniquely characterised by: substantial reconstruction-era + post-conflict healthcare-system rebuilding context; distinctive Kimadia State-owned dominant public-sector procurement model; historical ~30+ domestic manufacturers under SCDI/SDI/NDI brands rebuilding capacity following 2003+ disruptions; substantial UN-agency + NGO humanitarian healthcare presence; substantial Internally Displaced Persons (IDP) + refugee population healthcare commitments; mixed Arabic + Kurdish labelling environment (Arabic federally + Kurdish in KRI); Climate Zone IVa + IVb (interior + coastal) pharmaceutical-stability environment with Iraqi summer ambient temperatures regularly exceeding 50°C.

Iraq MoH is an active League of Arab States Council of Arab Ministers of Health pharmaceutical-harmonisation co-leader + a WHO Eastern Mediterranean Regional Office (EMRO) participant + an active WHO Prequalification Collaborative Registration Procedure (CRP) participating authority + a WHO PIDM member + maintains substantial bilateral cooperation with EMA + FDA + Health Canada + TGA + Swissmedic + MHRA + MFDS + substantial trade-driven cooperation with Indian CDSCO + Turkish TİTCK + Iranian IFDA + Egyptian EDA + Jordanian JFDA reflecting Iraq's substantial pharmaceutical-import trade relationships.

Iraqi pharmaceutical regulation operates under a layered framework of Laws + Ministerial Orders + Technical Affairs Directorate Decisions + Guidance Documents — with distinct federal Iraq MoH (Baghdad) + Kurdistan Regional Government MoH (Erbil) frameworks:

• Law 40 of 1970 — Pharmacy Practice + Pharmaceutical Establishments federal framework.
• Law 68 of 1965 — Narcotics + Psychotropics framework substantively aligned with UN Single Convention 1961 + Conventions 1971 + 1988.
• Ministerial Orders + Technical Affairs Directorate Decisions on Drug Registration + Medical Devices + Cosmetics + Dietary Supplements.
• Iraqi MoH GMP Guide — substantively aligned with PIC/S GMP Guide + EU GMP + ICH Q7 + WHO TRS 986 Annex 2.
• Iraqi MoH GDP Guide — substantively aligned with WHO + EU GDP.
• Iraqi MoH GCP Guide — substantively aligned with ICH E6(R2).
• Iraqi MoH GVP Guide — substantively aligned with ICH E2 + EU GVP.
• Pharmacopoeia recognition — recognises British Pharmacopoeia + USP + European Pharmacopoeia + Indian Pharmacopoeia + Arab Pharmacopoeia.
• Iraqi National Essential Medicines List — substantial framework given Kimadia State-owned procurement dominance.
• Iraqi MoH Medical Devices framework — Class I-III risk-based classification substantively aligned with EU MDR + GHTF/IMDRF.
• Iraqi MoH Cosmetics framework — substantively aligned with EU Cosmetics Regulation including INCI ingredient listing + safety substantiation.
• Iraqi MoH Variations + 5-year Drug Registration Renewal framework.
• Kimadia Tender Framework — distinctive substantial framework given Kimadia State-owned procurement dominance; pre-qualification + tender + post-tender quality verification + distribution.
• Kurdistan Regional Government (KRG) MoH Pharmaceutical Framework — constitutionally-distinct parallel framework for KRI three Governorates; substantively similar to federal Iraq MoH but with KRG-specific Drug Registration + Pharmaceutical Inspection + Pharmacovigilance + procurement frameworks.
• UN-Agency Humanitarian Importation Framework — substantial framework given WHO + UNICEF + UNHCR + UNFPA + UNDP + ICRC + NGO humanitarian-imported medicines + devices for IDP + refugee + vulnerable-population healthcare programmes.

The National Center for Drug Control and Research (NCDCR) is Iraq MoH's central pharmaceutical quality-control laboratory + applied pharmaceutical research centre + is pursuing ISO/IEC 17025 scope expansion + WHO PQ-Lab designation. Kimadia (State Company for Marketing Drugs and Medical Appliances) is Iraq's distinctive State-owned pharmaceutical + medical-device procurement + distribution company — substantively unique within the Arab region in scale + scope — handling the dominant share of Iraqi public-sector pharmaceutical procurement + distribution + operating substantial post-tender quality verification + central distribution infrastructure.

• ISO/IEC 17025 — NCDCR pursuing ISO/IEC 17025 scope expansion across pharmaceutical chemical + microbiological + biological testing.
• WHO PQ-Lab Candidate — NCDCR pursuing WHO PQ-Lab designation; would position alongside Saudi SFDA Central Laboratory + Egypt EDA NODCAR + Morocco LNCM + Tunisia LNCM + Jordan JFDA Central Laboratories as WHO-prequalified pharmaceutical QC laboratories in the MENA region.
• Vaccine lot release — NCDCR conducts vaccine lot-release testing for Iraq MoH + the Iraqi Expanded Programme on Immunization including UNICEF + WHO + Gavi-supported procurement.
• Pharmaceutical pre-registration + post-market testing — pre-registration quality testing + post-market surveillance + targeted enforcement testing.
• Kimadia post-tender quality verification — distinctive substantial role given Kimadia State-owned procurement dominance; post-tender quality verification + pre-distribution acceptance testing + counterfeit + substandard medicine forensic capacity.
• Medical-device + IVD testing — pre-market + post-market quality testing.
• Cosmetic-product + dietary-supplement testing — safety + ingredient compliance testing.
• Counterfeit-medicine forensics — forensic analytical support for Iraq MoH + Ministry of Interior + Iraqi Customs investigations + WHO Global Surveillance & Monitoring System contributions.
• Capacity-building — hosts WHO + Arab League + EMA + USP capacity-building programmes + training for Iraqi + KRI pharmaceutical analysts.
• GMP Inspectorate support — provides scientific + technical support for Iraq MoH Pharmaceutical Inspection Department GMP inspections of Iraqi + foreign manufacturing facilities.
• Iraqi domestic manufacturer support — supports State Company for Drug Industries (SCDI Samarra) + Samarra Drug Industries (SDI) + Nineveh Drug Industries (NDI) + emerging private-sector domestic manufacturers rebuilding post-2003 + post-2014 ISIS-conflict capacity.
• Reconstruction + humanitarian medicine quality — distinctive substantial role given substantial UN-agency + NGO humanitarian-procured medicines + reconstruction-era public-health programmes requiring post-market quality verification.

Iraq MoH medical-device + IVD regulation operates under Iraqi MoH Medical Devices framework with Class I-III risk-based classification substantively aligned with EU MDR + GHTF/IMDRF. Foreign manufacturers must appoint an Iraqi Authorised Representative. Iraq's medical-device market is served by both Iraqi-domestic + foreign manufacturers + substantial UN-agency + NGO humanitarian-imported devices for IDP + refugee + vulnerable-population healthcare + substantial Kimadia State-owned medical-device procurement + distribution + parallel KRG MoH medical-device framework for KRI three Governorates.

• Risk-based Classification (Class I / IIa / IIb / III) — substantively aligned with EU MDR + GHTF/IMDRF; IVDs classified under separate framework.
• Iraqi Authorised Representative — Iraq-resident legal entity required for foreign manufacturers; bears post-market vigilance responsibility + Iraq MoH regulatory interface.
• KRG Authorised Representative — KRI-resident legal entity required for foreign manufacturers targeting KRI three Governorates; parallel KRG MoH regulatory interface.
• ISO 13485:2016 — recognised by Iraq MoH + KRG MoH as QMS evidence framework; Iraq + KRI-specific overlay required.
• Reliance pathways — Iraq MoH accepts CE Mark + FDA 510(k) + FDA PMA + Health Canada + TGA + Swissmedic + MFDS + Japan-approval evidence as supporting evidence; CE Mark + FDA particularly central.
• Arab League Medical Devices Harmonisation — Iraq participates in Council of Arab Ministers of Health medical-device harmonisation.
• Kimadia Medical Device Tender — distinctive substantial framework given Kimadia State-owned medical-device procurement dominance.
• KRG Medical Device Procurement — parallel KRG Kimadia-equivalent (Kurdistan Region General Directorate of Pharmaceuticals + Medical Appliances Procurement) medical-device procurement for KRI three Governorates.
• Post-market vigilance — Iraq MoH + KRG MoH operate parallel medical-device adverse-event reporting; reporting timelines substantively aligned with IMDRF Adverse Event Reporting Codes.
• IVD Réactovigilance — Iraq MoH operates IVD réactovigilance reflecting Iraq's clinical-laboratory infrastructure including teaching hospitals + private-sector laboratories.
• Cosmetic Notification — cosmetics require Iraq MoH Cosmetic Notification + Arabic labelling (Kurdish additionally required in KRI); INCI-aligned ingredient listing + safety substantiation; substantively EU-aligned framework.
• Dietary Supplement Registration — Iraq MoH Dietary Supplements framework; substantively aligned with EU food-supplement framework + Codex Alimentarius.
• Humanitarian Device Importation — substantial UN-agency + NGO humanitarian medical-device + IVD importation framework for IDP + refugee + vulnerable-population healthcare programmes; coordinated with WHO + UNHCR + UNICEF + UNFPA + UNDP + ICRC + IRC + MSF.
• Importation Permit — Iraq MoH Importation Permit required in addition to product registration for foreign-manufactured devices + drugs entering Iraq; coordination with Iraqi Customs + Ministry of Trade; parallel KRG Importation Permit for KRI.

Iraq MoH operates the Iraqi Pharmacovigilance Center (IPVC). Iraq is a WHO Programme for International Drug Monitoring (PIDM) member + contributes ADR data to VigiBase via Uppsala Monitoring Centre (UMC). The IPVC coordinates with university teaching hospitals + private hospitals + Kimadia post-tender pharmacovigilance + UN-agency + NGO humanitarian-healthcare operators + parallel KRG MoH Pharmacovigilance Center for KRI three Governorates. Iraq's pharmacovigilance is uniquely shaped by substantial IDP + refugee + vulnerable-population vaccine + essential-medicines safety surveillance commitments + reconstruction-era supply-chain quality risk monitoring + Kimadia State-owned procurement post-tender pharmacovigilance + substantial counterfeit + substandard medicine surveillance commitments.

• Iraqi Pharmacovigilance Center (IPVC) — coordinated by Iraq MoH Technical Affairs Directorate.
• WHO PIDM Member — Iraq is a WHO PIDM member + contributes ADR data to VigiBase via Uppsala Monitoring Centre.
• Iraqi PV Network — coordinated national network with effector centres in major Iraqi university teaching hospitals (Baghdad Medical City, Al-Imamain Al-Kadhmain Medical City, Al-Yarmouk Teaching Hospital, Al-Kindi Teaching Hospital, Basrah Teaching Hospital, Mosul Teaching Hospital, Karbala Teaching Hospital, Najaf Teaching Hospital) + Marketing Authorisation Holders + Kimadia post-tender pharmacovigilance.
• KRG MoH Pharmacovigilance Center — parallel KRG PV centre coordinating KRI three Governorates pharmacovigilance with effector centres at KRI university teaching hospitals (Erbil Teaching Hospital, Sulaimani Teaching Hospital, Duhok Teaching Hospital).
• ADR Reporting — Iraq MoH operates ADR reporting via Iraq MoH portal; available for healthcare professionals + consumers + Marketing Authorisation Holders.
• E2B(R3) ICSR — Iraq MoH accepts E2B(R3) format ICSR submissions substantively aligned with ICH E2B(R3); 15-day SUSAR reporting timeline for clinical trials + post-market.
• PSUR / PBRER — periodic safety update reports substantively aligned with ICH E2C(R2); Iraq MoH-specific submission timeline.
• Risk Management Plans (RMP) — Iraq MoH requires ICH E2E-aligned Pharmacovigilance Plan + Risk Management Plan for new drugs + biosimilars + vaccines + high-risk products.
• Active surveillance — Iraqi PV Center operates targeted active-surveillance programmes for COVID-19 vaccines + childhood immunisation + oncology + biologicals.
• IDP + refugee + vulnerable-population PV — distinctive substantial commitments for Internally Displaced Persons + Syrian refugee + Iraqi-vulnerable-population vaccine + essential-medicines safety surveillance coordinated with UNHCR + UNICEF + UNFPA + WHO.
• AEFI Surveillance — Iraqi vaccine adverse-event surveillance aligned with WHO methodology; central to Iraqi Expanded Programme on Immunization + UNICEF + Gavi + WHO-supported immunisation campaigns.
• Matériovigilance + Cosmétovigilance — Iraq MoH operates parallel matériovigilance for medical devices + cosmétovigilance for cosmetics.
• Kimadia post-tender pharmacovigilance — distinctive substantial role given Kimadia State-owned procurement dominance; post-tender pharmacovigilance + Kimadia distribution-network ADR signal aggregation.
• Counterfeit + substandard medicine surveillance — distinctive substantial role given reconstruction-era supply-chain disruption + Iraq's geographic position at MENA crossroads creating substantial counterfeit + substandard medicine quality risks.
• Arab League Pharmacovigilance — Iraq participates in Arab League Council of Arab Ministers of Health pharmacovigilance harmonisation.

• WHO EMRO Participant — Iraq MoH is an active WHO Eastern Mediterranean Regional Office (EMRO) participant; substantial WHO + UN-agency humanitarian healthcare cooperation.
• WHO PQ CRP Participating Authority — Iraq MoH is an active WHO Prequalification Collaborative Registration Procedure (CRP) participating authority.
• WHO PQ-Lab Candidate — NCDCR pursuing WHO PQ-Lab designation.
• WHO PIDM Member — Iraq contributes ADR data to VigiBase via Uppsala Monitoring Centre.
• Arab League Council of Arab Ministers of Health Co-leader — Iraq MoH is an active pharmaceutical-harmonisation co-leader alongside Egyptian EDA + Saudi SFDA + Jordanian JFDA + UAE MoHAP + Lebanese MoPH + Morocco DMP + Tunisia DPM/ANPM + Algeria ANPP + Kuwait MoH + Bahrain NHRA + Oman MoH + Qatar MoPH.
• EMA Cooperation — Iraq MoH maintains substantial EU reliance practice for high-end + biologicals + specialty pharmaceuticals including French + German + Italian + Spanish + EMA centralised + decentralised authorisation reliance.
• FDA Bilateral — Iraq MoH maintains substantial FDA cooperation reflecting reconstruction-era + post-conflict bilateral cooperation + USAID + US Department of Defense healthcare programming.
• Health Canada + TGA + Swissmedic + MHRA + MFDS Bilateral — Iraq MoH maintains Stringent Regulatory Authority reliance practice.
• Indian CDSCO Bilateral — distinctive substantial trade-driven cooperation reflecting India being one of Iraq's largest pharmaceutical import sources; CDSCO-approved generics dominate substantial Kimadia tender categories.
• Turkish TİTCK Bilateral — substantial trade-driven cooperation reflecting Turkey's substantial pharmaceutical export trade with Iraq + KRI.
• Iranian IFDA Bilateral — substantial trade-driven cooperation reflecting Iran's substantial pharmaceutical export trade with Iraq, particularly central + southern Iraq.
• PIC/S Cooperation — Iraq MoH GMP Guide substantively aligned with PIC/S GMP + EU GMP + ICH Q7; PIC/S Pre-Accession dialogue.
• ICH Observer Practice — ICH guidelines extensively implemented in Iraqi regulatory practice including ICH Q7 + Q8 + Q9 + Q10 + Q11 + E2A-E + M4.
• ICDRA + EMRO participation — active International Conference of Drug Regulatory Authorities + WHO EMRO participant.
• UN-Agency Humanitarian Cooperation — substantial cooperation with WHO + UNICEF + UNHCR + UNFPA + UNDP + ICRC + IRC + MSF + Iraqi Red Crescent Society for IDP + refugee + vulnerable-population healthcare programmes; among most substantial UN-agency humanitarian pharmaceutical operational frameworks globally.
• Reconstruction-era Bilateral Cooperation — substantial reconstruction-era + post-conflict bilateral cooperation with USAID + EU + UK FCDO + Japan JICA + German GIZ + Italian + French + Spanish + Norwegian bilateral development agencies.

• Federal Iraq MoH vs KRG MoH parallel-registration strategy missed — most operationally significant feature of Iraqi pharmaceutical market access frequently overlooked; foreign manufacturers targeting all-of-Iraq must engage both federal Iraq MoH (Baghdad — ~38 million population, 15 Governorates) + KRG MoH (Erbil — ~6 million population, 3 KRI Governorates) with substantively parallel but distinct registration procedures.
• Iraqi Authorised Representative not properly designated — application rejected at Iraq MoH intake or post-approval compliance failure; Iraqi Authorised Representative must be Iraq-resident legal entity with appropriate licensure; separate KRG Authorised Representative required for KRI.
• Arabic + Kurdish labelling deficiencies — Arabic required federally + Kurdish required in KRI; many applicants provide insufficient Kurdish-language patient leaflet for KRI market access.
• Iraq MoH GMP gaps — applicants assuming EU GMP / PIC/S GMP / FDA GMP compliance is automatically sufficient without addressing Iraq-specific Iraq MoH GMP clarifications.
• Iraq climate-zone stability data missing — Iraq is Climate Zone IVa (interior — Baghdad / Basra / Mosul) + Climate Zone IVb (coastal — Basra-Gulf) requiring substantial zonal-specific stability data particularly for Iraqi summer ambient conditions regularly exceeding 50°C.
• Kimadia tender pre-qualification missed — distinctive substantial framework given Kimadia State-owned procurement dominance; pre-qualification provides Iraqi public-sector market access via Kimadia tender; frequently overlooked by foreign manufacturers targeting only private-sector Iraqi pharmaceutical market.
• KRG Kimadia-equivalent (Kurdistan Region General Directorate of Pharmaceuticals + Medical Appliances Procurement) procurement strategy missed — parallel KRG public-sector procurement framework frequently overlooked.
• Bioequivalence centres + biowaiver — Iraq MoH BE Guidance provides BCS-based biowaivers; applicants frequently submit BE studies where biowaivers would suffice.
• WHO PQ CRP reliance under-utilised — WHO-PQ-approved products eligible for accelerated Iraq MoH CRP review (90-120 day target); under-utilised by many applicants.
• EMA + SRA reliance under-utilised — Iraq MoH operates substantial reliance on EMA + Stringent Regulatory Authority decisions.
• Arab League harmonisation not leveraged — Council of Arab Ministers of Health pharmaceutical-harmonisation reliance under-utilised.
• Trade-partner reliance (India CDSCO / Turkey TİTCK / Egypt EDA / Jordan JFDA) under-utilised — distinctive substantial trade-driven reliance reflecting Iraq's pharmaceutical-import trade relationships; particularly substantial for Indian-CDSCO-approved generics dominating Kimadia tender categories.
• UN-Agency humanitarian procurement pathway not leveraged — substantial WHO + UNICEF + UNHCR + UNFPA + UNDP humanitarian procurement opportunity for IDP + refugee + vulnerable-population healthcare programmes frequently overlooked.
• Essential Medicines + Vital Medicines accelerated pathway not leveraged — accelerated Registration under-utilised; 90-120 calendar day target.
• Counterfeit + substandard medicine quality risks under-monitored — Iraq's reconstruction-era supply-chain disruption + geographic MENA crossroads position create substantial counterfeit + substandard medicine quality risks requiring substantial post-market quality surveillance frequently overlooked.
• Variations strategy not planned — variations procedure substantively similar to EU but with Iraq-specific timelines + fee structure + administrative delays; parallel KRG variations procedure for KRI.
• Registration renewal timing missed — 5-year renewal must be filed within prescribed window before expiry; missed deadline triggers de-registration; parallel KRG renewal for KRI.
• Clinical trial ethics coordination steps — Iraq clinical trials require Iraq MoH CTA + relevant Institutional Review Board (University of Baghdad / Al-Mustansiriya / University of Mosul / University of Basra / KRI medical-school IRB) approval; Iraq's substantial post-conflict reconstruction clinical-research rebuilding capacity provides emerging opportunity.

V5 Ultimate provides the operational infrastructure Iraqi + KRI + foreign-supplier sites need for Law 40 of 1970 + Iraq MoH GMP + Medical Devices framework + WHO PQ CRP + EMA + SRA reliance + Arab League + Indian CDSCO + Turkish TİTCK + Egyptian EDA + Jordanian JFDA trade-partner reliance + Iraqi Pharmacovigilance Center + UN-agency humanitarian procurement + Kimadia State-owned tender + parallel KRG MoH registration readiness.

• Iraq MoH GMP control framework — PIC/S + EU GMP + ICH Q7 + WHO TRS 986 Annex 2-aligned controls with ALCOA+ data-integrity + Iraq-specific clarifications + Climate Zone IVa + IVb stability monitoring for Iraqi summer ambient conditions regularly exceeding 50°C.
• Iraq MoH Registration dossier packaging — Iraq CTD-aligned dossier structure with Iraq Module 1 specifics + Module 3 stability + Arabic patient leaflet + Authorised Representative declarations + Law 40 of 1970 framework.
• KRG MoH parallel Registration workflow — distinctive parallel Drug Registration packaging for KRI three Governorates (Erbil + Sulaymaniyah + Duhok) with Kurdish-language patient leaflet + KRG Authorised Representative declarations + KRG MoH framework — most operationally significant feature of Iraqi pharmaceutical market access frequently overlooked.
• WHO PQ CRP workflow — Iraq MoH-as-CRP-participating-authority packaging with reduced dossier + accelerated Iraq MoH review (90-120 day target).
• EMA + FDA + SRA reliance workflow — Iraq MoH-EMA + Iraq MoH-FDA + Iraq MoH-Health Canada + TGA + Swissmedic + MHRA + MFDS reliance packaging.
• Arab League workflow — Council of Arab Ministers of Health pharmaceutical-harmonisation packaging.
• Trade-partner reliance workflow (India CDSCO / Turkey TİTCK / Egypt EDA / Jordan JFDA) — distinctive substantial trade-driven reliance packaging reflecting Iraq's substantial pharmaceutical-import trade relationships; particularly substantial for Indian-CDSCO-approved generics dominating Kimadia tender categories.
• Kimadia State-owned tender workflow — distinctive substantial framework given Kimadia State-owned procurement dominance; pre-qualification + tender + post-tender quality verification + distribution packaging.
• KRG Kimadia-equivalent procurement workflow — parallel KRG public-sector procurement packaging for KRI three Governorates.
• UN-Agency humanitarian procurement workflow — WHO + UNICEF + UNHCR + UNFPA + UNDP + ICRC humanitarian procurement framework packaging for IDP + refugee + vulnerable-population healthcare programmes.
• Iraqi + KRG Authorised Representative workflow — foreign-manufacturer parallel Iraqi + KRG Authorised Representative designation + role-management + Iraq + KRI-specific post-market surveillance.
• Iraqi clinical-trial workflow — Iraq MoH CTA + University of Baghdad / Al-Mustansiriya / University of Mosul / University of Basra / KRI medical-school IRB coordination + Iraqi SUSAR reporting via Iraqi Pharmacovigilance Center; leverages Iraq's substantial post-conflict reconstruction clinical-research rebuilding capacity.
• Iraqi PV Center + KRG PV Center integration — E2B(R3) ICSR generation + 15-day SUSAR timeline + PSUR / PBRER packaging + Arabic + Kurdish ICSR + Iraqi PV Network + KRG PV Network coordination + VigiBase upload + Risk Management Plan packaging + AEFI vaccine adverse-event reporting + IDP + refugee + vulnerable-population safety surveillance + Kimadia post-tender pharmacovigilance.
• Matériovigilance + Cosmétovigilance workflow — parallel matériovigilance + cosmétovigilance packaging across federal Iraq + KRG.
• Medical-device + IVD + cosmetic + dietary-supplement workflow — Iraq MoH + KRG MoH frameworks dossier packaging + Class I-III classification + ISO 13485 + Authorised Representative + post-market vigilance.
• Counterfeit + substandard medicine surveillance workflow — Iraq's reconstruction-era supply-chain disruption + geographic MENA crossroads position monitoring + WHO Global Surveillance & Monitoring System integration.
• Essential Medicines + Vital Medicines accelerated workflow — Iraqi National Essential Medicines List + public-health emergency product packaging.
• Arab League + Mashreq + trade-partner regional bridging — for companies operating across Arab League + Mashreq + Indian + Turkish + Iranian + Egyptian + Jordanian trade-partner jurisdictions, V5 surfaces Iraq MoH + KRG MoH + Lebanon MoPH + Jordan JFDA + Egyptian EDA + Saudi SFDA + UAE MoHAP + India CDSCO + Turkey TİTCK + Iran IFDA harmonised dossier-element reuse alongside national-specific extensions.